Erbitux fails another trial, threatening Merck's hoped-for expansion

It's another stumble for Erbitux. The cancer drug failed its second Phase III trial in months, Merck KGaA said, setting back the company's efforts to expand its use into stomach cancer. In May, Erbitux fell short in adjuvant treatment after colon-cancer surgery. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.